Advances and Future Prospects in Oncolytic Virus Immunotherapy

Dear Colleagues,

Oncolytic viruses (OVs) have attracted special attention due to their ability to self-propagate in the tumou microenvironment and selectively induce the lysis of cancer cells while sparing normal tissues. Growing evidence indicates that OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, and, in particular, with other immunotherapeutics. There are more than 40 OVs from at least nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, mechanisms of action, and advantages to be exploited, but also disadvantages to be mitigated. This collection of Cancers wants to provide a reference point for both basic scientists and clinicians operating in the OV field and, in general, in cancer (immuno)therapy. It will feature original articles describing cutting-edge research in this rapidly evolving field. We also aim to publish authoritative reviews summarizing the state of the art and the new challenges facing oncolytic virus immunotherapy to become a new pillar of cancer treatment.

Dr. Antonio Marchini
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.